PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Public ClinicalTrials.gov record NCT06366451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592
Study identification
- NCT ID
- NCT06366451
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- AZD9592 Biological
- AZD9592 + Pembrolizumab Combination Product
- AZD9592 + Rilvegostomig Combination Product
- AZD9592 + Sabestomig Combination Product
- AZD9592 + Volrustomig Combination Product
- Pembrolizumab Biological
- Rilvegostomig Biological
- Sabestomig Biological
- Volrustomig Biological
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2024
- Primary completion
- Jan 31, 2025
- Completion
- Mar 31, 2025
- Last update posted
- Jan 19, 2025
2024 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Recruiting |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | Recruiting |
| Oregon Health & Science University (OHSU) | Portland | Oregon | 97239 | Not yet recruiting |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Sarah Cannon Medical Center | Charleston | South Carolina | 29406 | Recruiting |
| Medical University of South Carolina | Charleston | South Carolina | 29407 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Head and Neck Squamous Cell Carcinoma trials
Other public records listing Head and Neck Squamous Cell Carcinoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07441681: Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Recruiting
- NCT07744126: A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Not yet recruiting
- NCT07667400: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer Not yet recruiting
- NCT07602842: A Study of IDP-001 in Advanced or Metastatic Solid Tumors Recruiting
- NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Recruiting
- NCT03247712: Neoadjuvant Immunoradiotherapy in Head & Neck Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06366451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06366451 live on ClinicalTrials.gov.